Attached files
| file | filename |
|---|---|
| EX-99.1 - RADIENT PHARMACEUTICALS Corp | v240835_ex99-1.htm |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 ACT REPORTING REQUIREMENTS
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
Date of Report (Date of Earliest Event Reported): November 15, 2011
Radient Pharmaceuticals Corporation
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-16695
|
33-0413161
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
2492 Walnut Avenue, Suite 100, Tustin, California, 92780-7039
(Address of principal executive offices (zip code))
714-505-4461
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))
Section 7 – Regulation FD
Item 7.01 – Regulation FD Disclosure
Section 8 – Other Events
Item 8.01: Other Events
On November 14, 2011, DHS Holding Co. issued a press release announcing that it will enter into preliminary talks with us to discuss business opportunities that would benefit both parties. However, that press release was issued without our approval and we do not intend to have any further discussions, or enter into any business opportunities with DHS Holding Co.
On today’s date, we issued a press release disclosing same, along with our request and our counsel’s request that DHS Holding Co.immediately retract the press release at issue.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
|
Exhibit No.
|
Description
|
|
99.1
|
Press Release
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 15, 2011
|
RADIENT PHARMACEUTICALS CORPORATION
|
|
By: /s/ Akio Ariura
Chief Financial Officer